National OncoVenture Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Papitrol (tirvalimogene teraplasmid) / Genexine, National OncoVenture

GENUINE, NCT05286060: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Recruiting

RoW

GX-188E, GX-I7, Pembrolizumab, GX-188E, Pembrolizumab, GX-188E, GX-I7

Yonsei University, Genexine, Inc., NeoImmuneTech

Head and Neck Squamous Cell Carcinoma

08/25

12/25

TRINITY, NCT05280457: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy

Recruiting

RoW

nivolumab-GX-188E-GX-I7

Yonsei University

Head and Neck Squamous Cell Carcinoma

03/26

KEYNOTE-567, NCT03444376: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Completed

1/2

RoW

GX-188E, Ichor Tri-Grid Delivery System, KEYTRUDA®, pembrolizumab

Genexine, Inc., Merck Sharp & Dohme LLC

Cervical Cancer

04/22

12/23

vactosertib (TEW-7197) / National OncoVenture, Theragen Etex

NCT04656002: As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Not yet recruiting

Vactosertib, TEW-7197

Samsung Medical Center

Gastric Cancer

12/23

12/24

MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Withdrawn

RoW

Vactosertib, Imatinib

MedPacto, Inc.

Dermoid

05/22

MP-VAC-205, NCT04515979: Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Terminated

RoW

Vactosertib 300 mg BID and pembrolizumab 200 mg IV, Vactosertib 300 mg BID and keytruda 200 mg IV

MedPacto, Inc.

Carcinoma, Non-Small-Cell Lung

08/24

NCT04103645: Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Terminated

Vactosertib, TEW-7197

Weill Medical College of Cornell University

Myeloproliferative Neoplasm

07/24

NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn

Vactosertib(TEW-7197)/ Durvalumab

MedPacto, Inc., AstraZeneca

Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma

12/23

12/24

NCT04893252: Vactosertib and Durvalumab in Gastric Cancer

Recruiting

RoW

durvalumab and vactosertib

Hark Kyun Kim

Stomach Neoplasm

12/23

NCT03844750: Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Active, not recruiting

Hepatectomy, Liver Resection, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Vactosertib, EW-7197

Chloe Atreya, MD, PhD, Merck Sharp & Dohme LLC, MedPacto, Inc.

Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

04/26

NCT05436990: Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Terminated

RoW

Pembrolizumab, Vactosertib

Yonsei University

Acral Melanoma, Mucosal Melanoma

03/25

NCT06044311: Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Recruiting

Vactosertib, Oral TGF-beta Receptor I Inhibitor, Standard of Care Chemotherapy, Carboplatin, Paciltaxel, Concurrent Radiation

Sakti Chakrabarti

Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction

12/26

06/27

KEYNOTE 900, NCT03724851: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Completed

1/2

120

RoW

TEW-7197, vactosertib

MedPacto, Inc., Merck Sharp & Dohme LLC

Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

05/24

NCT03698825: TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

Completed

1/2

RoW

TEW-7197, vactosertib

MedPacto, Inc.

Metastatic Gastric Cancer

01/22

12/22

MP-VAC-203, NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Completed

1/2

RoW

TEW-7197, vactosetib

MedPacto, Inc., AstraZeneca

Non-Small Cell Lung Cancer Metastatic

05/24

NCT03802084: A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Completed

1/2

RoW

vactosertib/imatinib combination

Hyo Song Kim

Desmoid Tumor

03/24

NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting

1/2

US, RoW

Vactosertib, TEW-7197

MedPacto, Inc.

Osteosarcoma

09/25

12/25

MP-PDAC-01, NCT03666832: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel

Recruiting

RoW

TEW-7197, TEW-7197, FOLFOX

Joon Oh Park

Metastatic Pancreatic Cancer

12/22

12/23

NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting

RoW

Vactosertib, TEW-7197

Samsung Medical Center

Pancreas Cancer

12/22

03/23

CASE1A17, NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed

Vactosertib, TEW-7197, EW7197, EW-7197, Pomalidomide, POM

Koen van Besien

Multiple Myeloma

02/22

09/22

NCT05400122: Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Recruiting

Vactosertib, TEW-7197, EW-7197, EW7197, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, IL-2, Proleukin, Natural Killer Cells

David Wald

Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer

12/25

06/26

venadaparib (NOV 1401) / National OncoVenture, Ildong

NCT04725994: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Recruiting

1/2

100

US, RoW

IDX-1197+XELOX, IDX-1197+Irinotecan

Idience Co., Ltd.

Gastric Cancer

09/25

06/26

VASTUS, NCT04174716: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors

Completed

1/2

108

RoW

IDX-1197

Idience Co., Ltd.

Solid Tumors, Homologous Recombination Repair Gene Mutation, Homologous Recombination Deficiency

03/23

06/24

EU101 / Eutilex

NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting

1/2

110

US, RoW

EU101

Eutilex

Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer

09/25

12/25

NCT05060263: A Study of of HOT1030 in Patients With Advanced Solid Tumors

Recruiting

RoW

HOT-1030, no other interventions

Huabo Biopharm Co., Ltd.

Solid Tumor, Adult

06/23

DNP002 / Kumho HT, National OncoVenture

NCT06466265: Study of DNP002 in Patients With Solid Tumors

Recruiting

RoW

DNP002, H2319

Kumho HT Inc.

Advanced Solid Tumor

12/24

06/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Papitrol (tirvalimogene teraplasmid) / Genexine, National OncoVenture

GENUINE, NCT05286060: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Recruiting

RoW

GX-188E, GX-I7, Pembrolizumab, GX-188E, Pembrolizumab, GX-188E, GX-I7

Yonsei University, Genexine, Inc., NeoImmuneTech

Head and Neck Squamous Cell Carcinoma

08/25

12/25

Recruiting

RoW

nivolumab-GX-188E-GX-I7

Yonsei University

Head and Neck Squamous Cell Carcinoma

03/26

KEYNOTE-567, NCT03444376: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Completed

1/2

RoW

GX-188E, Ichor Tri-Grid Delivery System, KEYTRUDA®, pembrolizumab

Genexine, Inc., Merck Sharp & Dohme LLC

Cervical Cancer

04/22

12/23

vactosertib (TEW-7197) / National OncoVenture, Theragen Etex

Not yet recruiting

Vactosertib, TEW-7197

Samsung Medical Center

Gastric Cancer

12/23

12/24

MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Withdrawn

RoW

Vactosertib, Imatinib

MedPacto, Inc.

Dermoid

05/22

MP-VAC-205, NCT04515979: Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Terminated

RoW

Vactosertib 300 mg BID and pembrolizumab 200 mg IV, Vactosertib 300 mg BID and keytruda 200 mg IV

MedPacto, Inc.

Carcinoma, Non-Small-Cell Lung

08/24

NCT04103645: Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Terminated

Vactosertib, TEW-7197

Weill Medical College of Cornell University

Myeloproliferative Neoplasm

07/24

NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn

Vactosertib(TEW-7197)/ Durvalumab

MedPacto, Inc., AstraZeneca

Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma

12/23

12/24

NCT04893252: Vactosertib and Durvalumab in Gastric Cancer

Recruiting

RoW

durvalumab and vactosertib

Hark Kyun Kim

Stomach Neoplasm

12/23

NCT03844750: Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Active, not recruiting

Hepatectomy, Liver Resection, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Vactosertib, EW-7197

Chloe Atreya, MD, PhD, Merck Sharp & Dohme LLC, MedPacto, Inc.

Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8

04/26

NCT05436990: Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Terminated

RoW

Pembrolizumab, Vactosertib

Yonsei University

Acral Melanoma, Mucosal Melanoma

03/25

NCT06044311: Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Recruiting

Vactosertib, Oral TGF-beta Receptor I Inhibitor, Standard of Care Chemotherapy, Carboplatin, Paciltaxel, Concurrent Radiation

Sakti Chakrabarti

Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction

12/26

06/27

KEYNOTE 900, NCT03724851: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Completed

1/2

120

RoW

TEW-7197, vactosertib

MedPacto, Inc., Merck Sharp & Dohme LLC

Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

05/24

NCT03698825: TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

Completed

1/2

RoW

TEW-7197, vactosertib

MedPacto, Inc.

Metastatic Gastric Cancer

01/22

12/22

MP-VAC-203, NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Completed

1/2

RoW

TEW-7197, vactosetib

MedPacto, Inc., AstraZeneca

Non-Small Cell Lung Cancer Metastatic

05/24

NCT03802084: A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Completed

1/2

RoW

vactosertib/imatinib combination

Hyo Song Kim

Desmoid Tumor

03/24

NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting

1/2

US, RoW

Vactosertib, TEW-7197

MedPacto, Inc.

Osteosarcoma

09/25

12/25

Recruiting

RoW

TEW-7197, TEW-7197, FOLFOX

Joon Oh Park

Metastatic Pancreatic Cancer

12/22

12/23

NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting

RoW

Vactosertib, TEW-7197

Samsung Medical Center

Pancreas Cancer

12/22

03/23

CASE1A17, NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed

Vactosertib, TEW-7197, EW7197, EW-7197, Pomalidomide, POM

Koen van Besien

Multiple Myeloma

02/22

09/22

NCT05400122: Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Recruiting

David Wald

12/25

06/26

venadaparib (NOV 1401) / National OncoVenture, Ildong

NCT04725994: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer

Recruiting

1/2

100

US, RoW

IDX-1197+XELOX, IDX-1197+Irinotecan

Idience Co., Ltd.

Gastric Cancer

09/25

06/26

VASTUS, NCT04174716: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors

Completed

1/2

108

RoW

IDX-1197

Idience Co., Ltd.

Solid Tumors, Homologous Recombination Repair Gene Mutation, Homologous Recombination Deficiency

03/23

06/24

EU101 / Eutilex

NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting

1/2

110

US, RoW

EU101

Eutilex

Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer

09/25

12/25

NCT05060263: A Study of of HOT1030 in Patients With Advanced Solid Tumors

Recruiting

RoW

HOT-1030, no other interventions

Huabo Biopharm Co., Ltd.

Solid Tumor, Adult

06/23

DNP002 / Kumho HT, National OncoVenture

NCT06466265: Study of DNP002 in Patients With Solid Tumors

Recruiting

RoW

DNP002, H2319

Kumho HT Inc.

Advanced Solid Tumor

12/24

06/25



	Diseases Companies Products Productz Mechanisms of Action Sites